Prostate cancer: evading immunity, inspiring therapy
Trends in Cancer · 2026-11 · 12 (11) · 1081-1105
DOI: 10.1016/j.trecan.2026.07.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026-11. Verfasst von Bianca Calì und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oncology Research (IOR), Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerlan…. Hauptthemen laut MEDLINE: Tumor Escape, Prostatic Neoplasms, Immunotherapy. Die Arbeit nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Cancer Research.
Abstract (Originalsprache)
Prostate cancer (PCa) remains one of the most prevalent and lethal cancers in men, particularly in its metastatic form. Despite therapeutic advancements, resistance to therapy often leads to a castration-resistant state with genetic and molecular alterations that promote immune evasion and disease progression. Chronic inflammation and the immunosuppressive tumor microenvironment (TME) further exacerbate immune dysfunction. The suboptimal clinical success of current immunotherapies in advanced PCa underscores the urgent need to better understand the mechanisms underlying immune escape during disease progression and in response to therapeutic interventions. This review explores the key immune-evasive features of PCa, the contribution of the TME, and the immunotherapeutic strategies that have been clinically evaluated to improve outcomes in patients with advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Oncology Research (IOR), Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: bianca.cali@ior.usi.ch.
- Institute of Oncology Research (IOR), Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: danibri2014@gmail.com.
- Institute of Oncology Research (IOR), Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
- Institute of Oncology Research (IOR), Bellinzona, Switzerland.
- Institute of Oncology Research (IOR), Bellinzona, Switzerland; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland; Department of Health Sciences and Technology (D-HEST), ETH, Zurich,…
Förderung
- Swiss Cancer Research
Zitieren
APA
Calì, B., Brina, D., Moscarda, V., Kohl, A., Cetti, F., Bressan, S., & Alimonti, A. (2026). Prostate cancer: evading immunity, inspiring therapy. Trends in Cancer, 12(11), 1081-1105. https://doi.org/10.1016/j.trecan.2026.07.006
Vancouver
Calì B, Brina D, Moscarda V, Kohl A, Cetti F, Bressan S, et al. Prostate cancer: evading immunity, inspiring therapy. Trends in Cancer. 2026;12(11):1081-1105. doi:10.1016/j.trecan.2026.07.006
BibTeX
@article{Cal2026,
author = {Calì, Bianca and Brina, Daniela and Moscarda, Viola and Kohl, Anna and Cetti, Federica and Bressan, Silvia and Alimonti, Andrea},
title = {Prostate cancer: evading immunity, inspiring therapy},
journal = {Trends in Cancer},
year = {2026},
volume = {12},
number = {11},
pages = {1081--1105},
doi = {10.1016/j.trecan.2026.07.006}
}
EUVIMED